Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology. By Christina Jewett and ...

Practitioners nationwide are striving to do what’s best for children’s health, while staying supportive in the face of mistrust and confusion.

The increase in concern about rubella in Nigeria is not due to a brand-new outbreak, but rather the alarming convergence of long-standing low vaccination coverage, recent major outbreaks, and the ...

As the U.S. flu season winds down, health officials say the flu vaccine didn’t work very well, with one of its worst effectiveness rates in more than a decade. A new strain that dominated the early ...

Viral mismatch between circulating strains and vaccine may have weighed down effectiveness ...

Health experts are warning that the 2025-26 flu season isn't over yet. In fact, people should prepare for the virus to linger well into the warmer months, according to Dr. Michael Glazier, chief ...

Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday. About two weeks ago, the FDA sent Moderna a ...

DALLAS — In the last few weeks, there’s been an uptick in flu and norovirus cases across the country, and North Texas is feeling the impact. Eagle Mountain-Saginaw ISD’s Creekview Middle School in ...

The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, company and federal officials said ...

Debi Weiss thought her fatigue and weakness was a seasonal illness, but her condition quickly worsened.

Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. You’re listening to our weekly science news roundup. Let’s start off with a vaccine 180.